---
schema_version: "secwatch.filing_event.v1"
accession: "0001585364-26-000044"
form_type: "8-K"
ticker: "PRGO"
cik: "0001585364"
company_name: "PERRIGO Co plc"
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:43:28.440223+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook

## Summary
- All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.
- Core adjusted EPS $0.40, down 20% YoY; Core organic net sales -11.0% reflecting lower seasonal cough/cold and retailer destocking.
- After quarter end, completed Dermacosmetics sale for upfront cash of €306M; proceeds to support debt reduction.
- Self Care segment net sales down 11.5%, operating income down 39.3% due to lower volumes and prior-year manufacturing headwinds.
- Full-year 2026 outlook reaffirmed; expects second-half improvement from lapping headwinds and OEP.

## SEC filing metadata
- accession: 0001585364-26-000044
- form_type: 8-K
- ticker: PRGO
- cik: 0001585364
- company_name: PERRIGO Co plc
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/0001585364-26-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/prgo-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001585364-26-000044
- JSON: https://secwatch.observer/filing/0001585364-26-000044.json
- Plain text: https://secwatch.observer/filing/0001585364-26-000044.txt

## Key facts
- Earnings Releases
  PERRIGO Co plc reported the first quarter ended March 28, 2026 results: revenue $969 million, EPS $(2.81). Guidance reaffirmed.
  - Period: the first quarter ended March 28, 2026
  - Revenue: $969 million
  - EPS: $(2.81)
  - Guidance: reaffirmed
  - Result: reported results
  source text: of Women’s Health products. Core organic net sales comprised net pricing of 0.2% and volume/mix of -11.0%. • All In reported net sales declined 7.2% year over year to $969 million. The decrease was driven by the same factors impacting Core net sales, partially offset by Infant Formula net sales growth. Gross Margin • Reported gross margin was 33.6%, a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585364/000158536426000044/0001585364-26-000044-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.